OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy. - Wikidata - wikimedia - TriplyDB

OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy.

OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy.

http://www.wikidata.org/entity/Q44805706

about

Cancer immunotherapy: the beginning of the end of cancer?Tremelimumab: research and clinical development Influence of immunoglobulin isotype on therapeutic antibody function Principles of antibody-mediated TNF receptor activation Strategies for combining immunotherapy with radiation for anticancer therapy Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).Enhancement of Immune Effector Functions by Modulating IgG's Intrinsic Affinity for Target Antigen Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding Tumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor Therapy Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma.Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.OX40+ Regulatory T Cells in Cutaneous Squamous Cell Carcinoma Suppress Effector T-Cell Responses and Associate with Metastatic Potential.Therapeutic use of anti-CTLA-4 antibodies.OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some.FcγR requirements leading to successful immunotherapy.Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.Therapeutic targeting of CD70 and CD27.Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy.Role of Fc-FcγR interactions in the antitumor activity of therapeutic antibodies.Reversing T-cell Dysfunction and Exhaustion in Cancer.Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop Roles of regulatory T cells in cancer immunity.Cutting edge: epigenetic regulation of Foxp3 defines a stable population of CD4+ regulatory T cells in tumors from mice and humans.Targeting PD-1/PD-L1 in lung cancer: current perspectives.Ontogeny of Tumor-associated CD4+CD25+Foxp3+ T-regulatory Cells.Signaling by Antibodies: Recent Progress.Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease.Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity.Roles for Innate Immunity in Combination Immunotherapies.Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization.

P2860

Q26752277-C63F68EB-FEE0-47A6-A2B5-9E6B3916D7EF Q26752822-E0614DCD-D1B4-4A7E-A0BD-CD21C1130107 Q26772080-ABB59281-0CA5-4936-AC33-FDB9DF48859F Q26796270-B375CF9A-F701-4624-8B38-5210758B1A60 Q26796675-00CE85D9-0D8B-43CA-B304-5F2F4D85E96F Q28069864-561CE4B8-4CD4-4382-A309-D22C7DECA42A Q33705698-DCCEE5B0-A319-4B5F-8569-A6FF81657AF0 Q33707098-1000DAC0-337E-4014-9718-6F38BF6331AE Q34978570-4CF33BEC-74A1-474B-941E-389530B85115 Q36024656-171366A9-DF0A-4F5D-A3ED-3F60EE7FD14F Q36056627-CD621817-C7B9-44AD-9D05-C0E3DBCA831E Q36216363-261E1F0D-7AB2-417F-914D-0AF73D97038B Q36349514-09685AB3-0843-48CE-BE37-2082DEDE8B9B Q36498243-D394F68C-8A9B-44B4-9EFF-E1D5FE33A9C9 Q36907372-63A37995-A9AF-4504-916D-84A4A4F53D84 Q37114367-E2D3E8B1-1181-4E95-AD74-4CC2EE5EBBE4 Q37155745-D6180A26-022C-4B05-8CB0-0AA8FB32F543 Q37180457-30BA2AF4-D610-4B91-8485-DAE62FDA1F7C Q38231154-340CCD2F-BE60-4849-95C3-F5543D811F52 Q38374889-FD8C2067-5F56-42F5-A19D-6FABFE0730A0 Q38413904-23C927AF-8F3B-4908-83CD-B7CDF304AACA Q38615360-2AD5713E-673E-41F5-BC35-3D2E98176596 Q38746023-F62EE5B8-C204-49EC-B718-A9AF689C11DF Q38749841-6B646AF5-0CC0-4E10-9832-488E21F102FE Q38770814-FD329D1D-1B22-4F76-8F5B-5E03BA0E3CEE Q38779877-8DDF2154-B6C4-445A-B404-C358CF4317B3 Q38782706-B09509FC-C727-4E21-982A-E598114B9793 Q38809776-92DA513B-B61B-4B99-B031-B182B4001F52 Q38821875-E290601F-603E-42B5-BD0C-1E2D9C5AD2BB Q38830072-64C1F018-5FA3-465C-BD02-AB4CD0A0F484 Q38924558-88CC8A91-4B72-4910-A10E-DA1048D5ED4D Q38956294-4C93D186-B62A-40AA-A3FF-38C11CEF4542 Q38985262-7B487355-7D4D-4D8C-9661-E81F6C2A3864 Q39264890-0595CDE9-4E22-4E58-A6A1-B0080BE1E2FF Q39313794-26DF6ADA-F522-4E5E-963D-2456B4C58DB6 Q40560816-63C18CA1-3593-4DF2-989F-A195C4595927 Q41016369-A9AD4871-B570-49D7-9DA3-DD48F817E7B6 Q41101471-3350FFB8-3F41-4F45-B588-7FB50FB297BB Q41996352-DD725B20-8AC0-41AA-8F88-B1462DFA4A36 Q42280832-CCAB1794-FC3B-498B-89E6-E33CE45A1AB3

P2860

OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy.

http://www.wikidata.org/entity/Q44805706

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

OX40 engagement depletes intra ...... leading to antitumor efficacy.

@en

OX40 engagement depletes intra ...... leading to antitumor efficacy.

@nl

type

label

OX40 engagement depletes intra ...... leading to antitumor efficacy.

@en

OX40 engagement depletes intra ...... leading to antitumor efficacy.

@nl

prefLabel

OX40 engagement depletes intra ...... leading to antitumor efficacy.

@en

OX40 engagement depletes intra ...... leading to antitumor efficacy.

@nl

P1433

Q44805706-810499F3-D79C-4248-8230-43C0357FA6AA

P1476

Q44805706-255DEA71-C7EA-4B53-9C33-8D7718B4D02E

P2093

Q44805706-0BC7DADD-B034-4435-9A88-48076585D106

Q44805706-38A78D3A-9922-4164-8272-ABDB7AE3EA2D

Q44805706-45DD6664-AEF6-4FE2-91E2-7EFBED1B85A0

Q44805706-601C8FC4-7662-4533-A4B5-F395C9ACEFE2

Q44805706-AF7DCCD8-E7C7-47B0-9A84-D401C607C296

Q44805706-D09A502C-F06C-430D-8201-58297B535F7D

P2860

Q44805706-05CB3EF5-BF4D-47F8-8F8E-749D819CE5AD

Q44805706-09C9EB4C-0D60-43E6-9DFF-B3DDFAEF6C64

Q44805706-19A51BF9-35FF-4975-853F-C93AFE5545D9

Q44805706-1CAF8267-3693-4B22-9CEF-0F518D7A3D38

Q44805706-1E40AB24-D214-4B0B-8A05-16C15602E55B

Q44805706-26D35AC5-B12E-4EF9-B6C8-3C521FA7C2CC

Q44805706-31BB6A69-5262-4EB0-801C-ADA15C6F0D8D

Q44805706-3225A6F0-CC46-4DED-B9E0-E39946234448

Q44805706-40F80BAF-4E8B-4B2E-8773-91BD743734AF

Q44805706-53046883-2746-47A1-951B-B50CF7FABF0F

P304

Q44805706-4987313E-1112-41F2-AD8A-29A68E4C820D

P31

Q44805706-02ABA26E-9A16-4264-9126-634A184236C1

P356

Q44805706-F52392B6-C43F-4787-B28B-9E8C59E44512

P433

Q44805706-07689A25-56FA-40D0-AC62-84533A6F3F6C

P478

Q44805706-E0046292-5BEE-403F-9C48-3DE9BC7FA059

P577

Q44805706-2E87817D-3F2B-4609-A58A-1281CF78AE67

P698

Q44805706-BDC6237E-3DD4-41D7-93F7-3AAEF9CE82A5

P356

P1433

Immunology & Cell Biology

P1476

OX40 engagement depletes intra ...... leading to antitumor efficacy.

@en

P2093

Glenn Dranoff

http://www.w3.org/2001/XMLSchema#string

Jennifer L Brogdon

http://www.w3.org/2001/XMLSchema#string

Jimin Zhang

http://www.w3.org/2001/XMLSchema#string

Nicholas S Wilson

http://www.w3.org/2001/XMLSchema#string

Rose Jolicoeur

http://www.w3.org/2001/XMLSchema#string

Yannick Bulliard

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

Modulation of GITR for cancer immunotherapy

Science gone translational: the OX40 agonist story

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

Fcgamma receptors: old friends and new family members

Fcgamma receptors as regulators of immune responses

Cancer immunotherapy comes of age

An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.

Pancreatic islet xenograft survival in mice is extended by a combination of alpha-1-antitrypsin and single-dose anti-CD4/CD8 therapy.

P304

475-480

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/ICB.2014.26

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

92

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24732076

http://www.w3.org/2001/XMLSchema#string